J. Craig Venter's Human Longevity, Inc., is working toward new deals with biopharma companies. And the completion of the agreements could lead to a ramping up of HLI's already massive sequencing capacity.
J. Craig Venter's Human Longevity Inc. (HLI) has struck a deal with the Cleveland Clinic to access blood samples. The initial focus of the deal is on the sequencing and analysis of samples in Cleveland Clinic's GeneBank.
Feedback from an early-access program for Synthetic Genomics' personal DNA workstation has started to emerge. And the initial news is positive, with a researcher at the University of California, San Francisco, reporting that the device is cutting the time and money it takes to synthesize DNA.
Having given a $60 million boost to 23andMe last week, Genentech has now turned to J. Craig Venter's Human Longevity for help sequencing and analyzing tens of thousands of genomes.
A fresh wave of biopharma companies are partnering and investing in genome sequencing companies to integrate their data into the drug development process. The latest deal on this front pairs Roche with startup Human Longevity.
J. Craig Venter's Human Longevity, Inc. has added another piece to the data tapestry it is creating. The new addition is a registry of 11,000 twins, complete with phenotypic information and paired samples.
J. Craig Venter has made new hires at two of his companies.
While there is a well-established path from seed funding to exit for web startups, genomics plays with big ambitions require investors with deep pockets and an appetite for risk. Bryan Johnson seemingly has both and has set up a $100 million fund with the objective of turning "crazy" ideas into "viable" businesses.
Venter has gone to Mountain View to make his latest hire, nabbing Franz Och to build a Google Translate for genomics.
NIH has signed on to give the J. Craig Venter Institute $25 million over 5 years to study infectious diseases including influenza and malaria, working to spotlight new treatments.